OIS INDEX: Trump Bump

OIS Index: Trump Bump - Eye On Innovation Article - OIS - Healthegy

The OIS Index closed at 962.42 on Tuesday, a week after Donald Trump’s election. Here’s how the collection of 29 publicly traded ophthalmology companies fared against larger indexes.

OIS Index = 12.7% increase
Russell 3000 = 2.6% increase
NASDAQ Biotech Index = 11.2 % increase
US Medical Device Index = 1% drop

OIS Index | Trump Bump

SHARE THIS ARTICLE WITH YOUR COLLEAGUES:

RECOMMENDED FOR YOU

article-7-30

Virtual ASRS Reporter’s Notebook

OIS Virtual Public Company Showcase Panel

‘A Very Interesting Time’ and Other Insights from OIS Virtual Public Company Showcase

ois-nl-article-web

Retina Is Where the Research Is, and Other Big Players Want In

OIS Index Q2

OIS Index Rallies Back from COVID-Driven Decline

AbbVie Regroups after FDA Issues Complete Response Letter Rejecting Abicipar Pegol

AbbVie Regroups after FDA Issues Complete Response Letter Rejecting Abicipar Pegol

With Positive Phase III Results, Oyster Point Pharma Banks $120 Million from Public Offering

With Positive Phase III Results, Oyster Point Pharma Banks $120 Million from Public Offering

About The Author

Michael Lachman

Michael Lachman is President of EyeQ Research, which provides market research, analytics, and strategic advisory to ophthalmic companies and investors. Previously, he was a healthcare investment research analyst with Hambrecht & Quist, ThinkEquity Partners, and SAC Capital, and worked in business development, marketing, and R&D for Johnson & Johnson and Baxter.

SUBSCRIBE TO OUR NEWSLETTER

Get The Latest News In Opthalmologic Innovation To Your Inbox.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

SUBSCRIBE TO OIS WEEKLY

Get our monthly newsletter about the latest in opthalmologic innovation.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

STAY CONNECTED

NEW VIDEOS

PODCASTS